Open letter to Roche about oseltamivir trial data

BMJ (Online)

Volumn 345, Issue 7881, 2012, Pages

  Godlee, Fiona ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; OSELTAMIVIR;

ACCESS TO INFORMATION; CLINICAL RESEARCH; COCHRANE LIBRARY; DATA ANALYSIS; DRUG EFFICACY; DRUG FORMULARY; DRUG INDUSTRY; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; EDITORIAL; HUMAN; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PUBLIC HEALTH; RANDOMIZED CONTROLLED TRIAL (TOPIC); UNITED KINGDOM; WORLD HEALTH ORGANIZATION;

ACCESS TO INFORMATION; ANTIVIRAL AGENTS; CLINICAL TRIALS AS TOPIC; HUMANS; OSELTAMIVIR;

EID: 84868313319     PISSN: None     EISSN: 17561833     Source Type: Journal    
DOI: 10.1136/bmj.e7305     Document Type: Editorial

References (7)

1. Jefferson T, Jones M, Doshi P, Del Mar C. Neuraminidase inhibitors for preventing and treating influenza in healthy adults: systematic review and meta-analysis. BMJ 2009;339:b5106.
2. Doshi P. Neuraminidase inhibitors-the story behind the Cochrane review. BMJ 2009;339:b5164.
3. Cohen D. Complications: tracking down the data on oseltamivir. BMJ 2009;339:b5387.
4. Smith J, on behalf of Roche. Point-by-point response from Roche to BMJ questions. BMJ 2009;339:b5374.
5. Kaiser L, Wat C, Mills T, Mahoney P, Ward P, Hayden F. Impact of oseltamivir treatment on influenza-related lower respiratory tract complications and hospitalizations. Arch Intern Med 2003;163:1667-72.
6. Treanor JJ, Hayden FG, Vrooman PS, Barbarash R, Bettis R, Riff D, et al. Efficacy and safety of the oral neuraminidase inhibitor oseltamivir in treating acute influenza: a randomized controlled trial. US Oral Neuraminidase Study Group. JAMA 2000;283:1016-24.
7. Nicholson KG, Aoki FY, Osterhaus AD, Trottier S, Carewicz O, Mercier CH, et al. Efficacy and safety of oseltamivir in treatment of acute influenza: a randomised controlled trial. Neuraminidase Inhibitor Flu Treatment Investigator Group. Lancet 2000;355:1845-50.